## James W Patterson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11320713/publications.pdf

Version: 2024-02-01

172386 143943 3,371 80 29 57 citations h-index g-index papers 80 80 80 3599 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma. Cancer Research, 2012, 72, 1070-1080.	0.4	461
2	Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells. Journal of Clinical Oncology, 2003, 21, 4016-4026.	0.8	303
3	The perforating disorders. Journal of the American Academy of Dermatology, 1984, 10, 561-581.	0.6	208
4	Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting. Clinical Cancer Research, 2007, 13, 6386-6395.	3.2	149
5	Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule. Journal of Clinical Oncology, 2004, 22, 4474-4485.	0.8	141
6	Bowenoid papulosis: A clinicopathologic study with ultrastructural observations. Cancer, 1986, 57, 823-836.	2.0	129
7	MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma. Journal of Immunology, 2005, 174, 3080-3086.	0.4	121
8	Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. International Journal of Cancer, 2001, 92, 703-711.	2.3	114
9	Cutaneous involvement in Hodgkin's disease. Cancer, 1985, 55, 1136-1145.	2.0	109
10	Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens. Journal of Clinical Oncology, 2008, 26, 4973-4980.	0.8	108
11	PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. Oncolmmunology, 2016, 5, e1235107.	2.1	104
12	Rheumatoid Nodule and Subcutaneous Granuloma Annulare. American Journal of Dermatopathology, 1988, 10, 1-8.	0.3	95
13	Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma. Journal of Immunology, 2005, 174, 6863-6871.	0.4	91
14	Cutaneous involvement of multiple myeloma and extramedullary plasmacytoma. Journal of the American Academy of Dermatology, 1988, 19, 879-890.	0.6	77
15	Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. Journal of Cutaneous Pathology, 2004, 31, 247-253.	0.7	75
16	Solitary fibrous tumors of the skin: a clinicopathologic study of 10 cases and review of the literature. Journal of Cutaneous Pathology, 2007, 34, 844-850.	0.7	75
17	Primary Melanoma of the Skin and Cutaneous Melanomatous Metastases. American Journal of Clinical Pathology, 2004, 122, 70-77.	0.4	68
18	Keratosis punctata palmaris et plantaris and adenocarcinoma of the colon. Journal of the American Academy of Dermatology, 1984, 10, 587-591.	0.6	59

#	Article	IF	CITATIONS
19	The histological and pathogenetic spectrum of cutaneous disease in monoclonal gammopathies. Journal of Cutaneous Pathology, 2008, 35, 705-721.	0.7	59
20	Squamous cell carcinoma arising in Hailey-Hailey disease. Journal of the American Academy of Dermatology, 2000, 43, 368-371.	0.6	53
21	Cutaneous botryomycosis in a patient with acquired immunodeficiency syndrome. Journal of the American Academy of Dermatology, 1987, 16, 238-242.	0.6	49
22	Congenital Midline Hamartoma: Case Report with Histochemical and Immunohistochemical Findings. Pediatric Dermatology, 1990, 7, 199-201.	0.5	46
23	Cutaneous paraneoplastic syndromes. Seminars in Diagnostic Pathology, 2019, 36, 211-228.	1.0	43
24	ULTRASTRUCTURAL CHANGES IN ACQUIRED PERFORATING DERMATOSIS. International Journal of Dermatology, 1992, 31, 201-205.	0.5	40
25	Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. Journal of Translational Medicine, 2010, 8, 79.	1.8	38
26	"Clear Cell―Atypical Fibroxanthoma. The Journal of Dermatologic Surgery and Oncology, 1987, 13, 1109-1114.	0.8	36
27	Lipedematous alopecia: a clinicopathologic, histologic and ultrastructural study. Journal of Cutaneous Pathology, 2000, 27, 49-53.	0.7	35
28	The Vaccine-site Microenvironment Induced by Injection of Incomplete Freund's Adjuvant, With or Without Melanoma Peptides. Journal of Immunotherapy, 2012, 35, 78-88.	1.2	31
29	Bullous Pemphigoid International Journal of Dermatology, 1985, 24, 173-176.	0.5	30
30	Cytophagic Histiocytic Panniculitis—a Critical Reappraisal. Archives of Dermatology, 2000, 136, 922-4.	1.7	30
31	Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium. JAMA Dermatology, 2015, 151, 1117.	2.0	27
32	Problems in the interpretation of apparent †radial growth phase†malignant melanomas that metastasize. Journal of Cutaneous Pathology, 2002, 29, 407-414.	0.7	26
33	Progress in the Perforating Dermatoses. Archives of Dermatology, 1989, 125, 1121.	1.7	25
34	Perforating folliculitis and psoriasis. Journal of the American Academy of Dermatology, 1982, 7, 369-376.	0.6	24
35	VEGFRâ€2 expression in human melanoma: Revised assessment. International Journal of Cancer, 2011, 129, 2807-2815.	2.3	24
36	The spectrum of lichenoid dermatitis. Journal of Cutaneous Pathology, 1991, 18, 67-74.	0.7	21

#	Article	IF	CITATIONS
37	Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines. Annals of Surgical Oncology, 2008, 15, 3538-3549.	0.7	21
38	Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma. Melanoma Research, 2012, 22, 302-309.	0.6	21
39	Tumefactive lipedema with pseudoxanthoma elasticum-like microscopic changes. Journal of Cutaneous Pathology, 2004, 31, 205-209.	0.7	19
40	Application of Mohs micrographic surgery appropriate-use criteria to skin cancers at a university health system. Journal of the American Academy of Dermatology, 2014, 71, 29-35.	0.6	19
41	Multiple cutaneous lymphoproliferative disorders showing a retained tumor clone by <scp>T</scp> â€cell receptor gene rearrangement analysis: a case series of four patients and review of the literature. International Journal of Dermatology, 2016, 55, e62-71.	0.5	14
42	Two Patients With Hailey-Hailey Disease, Multiple Primary Melanomas, and Other Cancers. Archives of Dermatology, 2011, 147, 211.	1.7	13
43	Hyperpigmented scar due to minocycline therapy. Cutis, 2004, 74, 293-8.	0.4	13
44	Bullous Pemphigoid International Journal of Dermatology, 1985, 24, 173-176.	0.5	12
45	Cutaneous and visceral leishmaniasis during anti-TNFÎ $\pm$ therapy. Wiener Medizinische Wochenschrift, 2017, 167, 78-82.	0.5	12
46	Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist., 2021, 9, e002214.		11
47	Cancer of the male breast. International Journal of Dermatology, 2000, 39, 881-886.	0.5	10
48	Radiation-induced lichen sclerosus of the vulva. Wiener Medizinische Wochenschrift, 2017, 167, 74-77.	0.5	10
49	An Extracellular Body of Plasma Cell Origin in Inflammatory Infiltrates Within the Dermis. American Journal of Dermatopathology, 1986, 8, 117-123.	0.3	9
50	Telmisartan/hydrochlorothiazide-induced nevus-associated cutaneous melanoma: first report in the medical literature. Expert Review of Clinical Pharmacology, 2021, 14, 289-293.	1.3	6
51	Selected Pseudoneoplastic Lesions of the Skin. Archives of Pathology and Laboratory Medicine, 2010, 134, 369-377.	1.2	6
52	Cutaneous Melanocytic Lesions. Pathology Patterns Reviews, 2005, 124, S52-S83.	0.4	5
53	What's new in dermatopathology. Journal of the American Academy of Dermatology, 1989, 20, 101-113.	0.6	4
54	Erythema gyratum repens: aÂpathogenetic mystery and therapeutic challenge. Wiener Medizinische Wochenschrift, 2017, 167, 117-119.	0.5	4

#	Article	IF	Citations
55	Sclerosing epithelioid fibrosarcoma. Wiener Medizinische Wochenschrift, 2017, 167, 120-123.	0.5	4
56	Lymphomas. Dermatologic Clinics, 1992, 10, 235-251.	1.0	4
57	Immunohistology of Skin Tumors. , 2011, , 464-499.		3
58	Interdigital melanoma simultaneously affecting two neighboring interdigital spaces. Wiener Medizinische Wochenschrift, 2018, 168, 423-426.	0.5	3
59	A novel surgical margin (1 cm) might be from benefit for patients with dysplastic nevi, thin melanomas, and melanoma in situ: Analysis based on clinical cases. Dermatologic Therapy, 2020, 33, e13261.	0.8	3
60	Telmisartan (and/or nitrosamine) - induced occult melanoma: first reported case in world literature. Expert Review of Clinical Pharmacology, 2021, 14, 1075-1080.	1.3	3
61	Basal Cell Carcinoma Surgery: Simple Undermining Approach in Two Patients with Different Tumour Locations. Open Access Macedonian Journal of Medical Sciences, 2017, 5, 506-510.	0.1	3
62	A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence. Cancer Immunology, Immunotherapy, 2013, 62, 1327-1334.	2.0	2
63	Undermining plastic surgery as aÂpossible option for treating basal cell carcinoma of the forehead. Wiener Medizinische Wochenschrift, 2017, 167, 131-133.	0.5	2
64	Interstitial Granulomatous Dermatitis (IGD). Open Access Macedonian Journal of Medical Sciences, 2017, 5, 543-544.	0.1	2
65	Diagnostic histochemistry in non-neoplastic skin diseases. Seminars in Diagnostic Pathology, 2018, 35, 390-398.	1.0	2
66	Late Onset Achromatic Melanoma Arising in a Giant Congenital Melanocytic Nevus. Open Access Macedonian Journal of Medical Sciences, 2017, 5, 533-534.	0.1	2
67	A case of combined desmoplastic trichoepithelioma and compound melanocytic nevus. Journal of Cutaneous Pathology, 2017, 44, 657-659.	0.7	1
68	Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients., 2001, 92, 703.		1
69	Scleromyxedema (Arndt - Gottron Syndrome) Developing Under Tenofovir Treatment for Hepatitis B: Unique Presentation in a Bulgarian Patient!. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 782-785.	0.1	1
70	Multiple Primary Recurrent Basaliomas (mPR-BCCs) of the Scalp with Cranial Bone Invasion. Open Access Macedonian Journal of Medical Sciences, 2017, 5, 564-565.	0.1	1
71	Cutaneous tumors and tumor-like conditions. , 0, , 363-456.		1
72	Prescription for a professional life. Journal of Cutaneous Pathology, 2008, 35, 250-252.	0.7	0

#	Article	IF	CITATIONS
73	Giant Subcutaneous Solitary Gardner Fibroma of the Head of a Bulgarian Child. American Journal of Dermatopathology, 2017, 39, 950-952.	0.3	О
74	Granulomatous slack skin mycosis fungoides developing simultaneously with sarcoidâ€like lesions in a patient with repeated anabolic injections in the past?. Dermatologic Therapy, 2020, 33, e13200.	0.8	0
75	Giant subcutaneous Angiofibrolipoma: successful surgical approach in a Bulgarian patient. Acta Dermatovenerologica Alpina, Panonica Et Adriatica, 2016, 25, 25-6.	0.1	О
76	Pigmented Paraaxillary Located "Complex" Basal Cell Carcinoma Imitating clinically irritated Melanocytic Lesion - Succesfull Surgical Approach in Bulgarian Patient. Open Access Macedonian Journal of Medical Sciences, 2017, 5, 497-500.	0.1	0
77	Necrobiotic Disorders. , 2019, , 1-12.		0
78	Systemic Disease and the Skin. , 2022, , 491-601.		0
79	Necrobiotic Disorders. , 2022, , 465-476.		0
80	Systemic Disease and the Skin. , 2020, , 1-112.		0